Curis Lifesciences MD, chairman, board of directors and AGM
NSE: CURISPharmaceuticals & Biotechnology
Share price at the NSE close on 23 Oct 2026. Previous close ₹185.00.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price.
- ₹143 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 7 Jul 2026
- 20.6
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 7 Jul 2026
- 3.0
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonesince listing in Nov 2025
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record. The filing of 7 Jul 2026
- 14.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 7 Jul 2026
- 15.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 7 Jul 2026
- 0.46
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 4,000100.0% delivered
Curis Lifesciences board of directors
At the end of the quarter to Jun 2026, as the company filed it; changes since are in its announcements.
An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.
Statutory auditor
Named in the results for the quarter to Mar 2026.
- B.T. Vora & Co.Peer-review certificate valid to Feb 2026
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
Curis Lifesciences AGM and shareholder votes
Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.Curis Lifesciences share news and announcements
Annual general meeting, 29 Sep 2026
315 shareholders on the register on 22 Sep 2026; present: 5 promoters and 0 others; votes counted by Sachin Thakkar / Sachin Thakkar & Associates.The company's voting result (opens in a new tab)
To Receive, Consider And Adopt The Audited Standalone Financial Statements Of The Company Including Audited Balance Sheet As At 31st March, 2026, Statement Of Profit And Loss And Cash Flow Statement For The Year Ended On 31st March, 2026, Together With The Directors’ Report And The Auditors' Report ThereonMoreLess
Ordinary100.00% for0.00% againstAgainst: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 68.03% · promoters 100.00% · institutions 0.00% · other public 0.00%
- To Appoint A Director In Place Of Mr. Jaimik Mansukhlal Patel (Din: 07371003), Who Retires By Rotation And Being Eligible, Offers Himself For Reappointment And In This RegardOrdinaryPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 55.11% · promoters 81.00% · institutions 0.00% · other public 0.00%
- To Give Approval For Related Party TransactionsOrdinaryPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 38.78% · promoters 57.00% · institutions 0.00% · other public 0.00%
- To Appoint Mr. Devabhai Hamirbhai Jadeja (Din: 11604996) As An Independent Director Of The CompanySpecial100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 68.03% · promoters 100.00% · institutions 0.00% · other public 0.00%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Fines
Reported in the filing for the quarter to Jun 2026.
- Fine or penaltyNational Stock ExchangeSince 30 Jun 2026
Fines for noncompliance/delayed compliance with Regulation 23(9) for year ended March 2026
Noncompliance\ delayed compliance with Regulation 23(9) of SEBI Listing Regulations read with Fines as per SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 issued on July 11, 2023.
In the company's own words, from its latest governance filing.
Investor complaints and compliance
Quarter by quarter.
Investor complaints received and resolved, the company's own count
- Received
- Resolved
Open at the quarter's end
- The filing has a part on fines and penalties
- Yes
- The filing has a part on tax disputes
- No
The company's own answers in its filing.
How money raised was used
Reported for the quarter to Mar 2026.
| Raised | Amount raised | For | Set aside | Spent | Spent elsewhere |
|---|---|---|---|---|---|
| Public IssuesNov 2025 | 27.52 | Capital Expenditure towards Upgradation/Improvement of our existing Manufacturing Facilities | 2.44 | 0.00 | No |
| Public IssuesNov 2025 | 27.52 | Capital Expenditure towards Construction of a Storage Facility | 3.62 | 1.00 | No |
| Public IssuesNov 2025 | 27.52 | Prepayment/Repayment of outstanding Secured Loans | 1.86 | 1.82 | No |
| Public IssuesNov 2025 | 27.52 | Product Registrations in other countries | 2.69 | 0.00 | No |
| Public IssuesNov 2025 | 27.52 | Funding our Working Capital Requirements | 11.25 | 11.25 | No |
| Public IssuesNov 2025 | 27.52 | General Corporate Purpose | 2.85 | 2.89 | No |
| Public IssuesNov 2025 | 27.52 | Issue Related Expenses | 2.80 | 3.60 | No |